原癌基因K-ras抗体

Quantity size:

0.2ml

Concentration:

1mg/ml 原癌基因K-ras抗体  Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.

Background:

This gene, a Kirsten ras oncogene homolog from the mammalian ras gene family, encodes a protein that is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma原癌基因K-ras抗体, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region. [provided by RefSeq]

Ras, a proto-oncogene, is a small G-protein that has 3 primary isoforms (H-Ras, N-Ras, and K-Ras) that differ in there approximately 20 C-terminal amino acids. H-Ras was first discovered as a transforming product the retrovirus Harvey murine virus and K-Ras of Kirten sarcoma virus. Ras is a heavily studied target of both academic and pharmaceutical research because of its implications in various pathways and diseases as well as being mutated in a large number of human cancers. Ras is most notably the activator of the Erk/MAPK kinase pathway as activator of Raf, as well as an activator of PI3 Kinase (PI3K). In its oncogenic, mutated state, Ras is unable to hydrolyze GTP 原癌基因K-ras抗体to GDP, thus staying in an active state and activating numerous pathways including the MAPK pathway through its activation of Raf, but also others as well that include PI3 Kinase and RalGDS. One path that the pharmaceutical industry has taken to control Ras and its activity is by finding what some consider its Achilles’ heel. For its activation, Ras must localize to the plasma membrane, but interestingly, it lacks a transmembrane domain. To achieve this, Ras must first undergo a post-translational modification (PTM) known as prenylation or geranylation at its C-terminal CAAX motif. For this to take place, a controlled three step process must occur. The first step in the process is the prenylation or geranylation of the C in the CAAX motif that is initiated by the covalent attachment of farnesyl groups to the cysteine that is catalyzed by the . After this modification, the and heterodimer enzymes farnesyl transferases –aaX of the motif is proteolytically removed via Rce1 (Ras Converting Enzyme 1), a membrane associated endoprotease, by a mechanism that is still not fully understood. Finally, the C-terminal prenylcysteine is now methlylated by ICMT (Isoprenylcysteine Carboxymethyl 原癌基因K-ras抗体Transferase). These drugs have yet to pass clinical trials though and there is doubt that they will ever be successful in treating tumors associated with Ras activation.

Also known as:

C-K-RAS; c-Ki-ras; c-Ki-ras p21; Ha-ras; K-RAS B; K-RAS2A; K-RAS2B; K-RAS4A; KI-RAS; KI-RAS4B; KRAS; KRAS1; KRAS2; MGC7141; NS; NS3; p21; p21B; p21ras; RAS; RAS1; RASH; RASK2.

Specificity:

●

Rabbit Polyclonal IgG, affinity purified by Protein A.

●

Reacts with: Human, Mouse, Rat, .

●

原癌基因K-ras抗体Immunogen: KLH conjugated synthetic peptide derived from human K-ras.

●

Predicted Molecular Weight: 21kDa.

Storage:

Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).

Application:

WB=1:100-500  ELISA=1:500-1000  IHC-P=1:100-500  IHC-F=1:100-500  IF=1:100-500   
Not yet tested in other applications. 
Optimal working dilutions must be determined by the end user.

kl105Mu01神经生长因子(NGF)多克隆抗体Polyclonal Antibody to Nerve Growth Factor (NGF)

kl105Po01神经生长因子(NGF)多克隆抗体Polyclonal Antibody to Nerve Growth Factor (NGF)

kl105Ra01神经生长因子(NGF)多克隆抗体Polyclonal Antibody to Nerve Growth Factor (NGF)

kl105Si01神经生长因子(NGF)多克隆抗体Polyclonal Antibody to Nerve Growth Factor (NGF)

kl106Bo01神经营养因子3(NT3)多克隆抗体Polyclonal Antibody to Neurotrophin 3 (NT3)

kl106Ga01神经营养因子3(NT3)多克隆抗体Polyclonal Antibody to Neurotrophin 3 (NT3)

kl106Hu01神经营养因子3(NT3)多克隆抗体Polyclonal Antibody to Neurotrophin 3 (NT3)

kl106Mu01神经营养因子3(NT3)多克隆抗体Polyclonal Antibody to Neurotrophin 3 (NT3)

kl106Po01神经营养因子3(NT3)多克隆抗体Polyclonal Antibody to Neurotrophin 3 (NT3)

kl106Ra01神经营养因子3(NT3)多克隆抗体Polyclonal Antibody to Neurotrophin 3 (NT3)

kl107Hu01神经营养因子4(NT4)多克隆抗体Polyclonal Antibody to Neurotrophin 4 (NT4)

kl107Mu01神经营养因子4(NT4)多克隆抗体Polyclonal Antibody to Neurotrophin 4 (NT4)

kl107Ra01神经营养因子4(NT4)多克隆抗体Polyclonal Antibody to Neurotrophin 4 (NT4)

kl108Cp01骨保护素(OPG)多克隆抗体Polyclonal Antibody to Osteoprotegerin (OPG)

kl108Ga01骨保护素(OPG)多克隆抗体Polyclonal Antibody to Osteoprotegerin (OPG)

kl108Hu01骨保护素(OPG)多克隆抗体Polyclonal Antibody to Osteoprotegerin (OPG)

kl108Mu01骨保护素(OPG)多克隆抗体Polyclonal Antibody to Osteoprotegerin (OPG)

kl108Po01骨保护素(OPG)多克隆抗体Polyclonal Antibody to Osteoprotegerin (OPG)

kl108Ra01骨保护素(OPG)多克隆抗体Polyclonal Antibody to Osteoprotegerin (OPG)

kl109Bo01肌肌酸激酶(CKM)多克隆抗体Polyclonal Antibody to Creatine Kinase, Muscle (CKM)

kl109Ca01肌肌酸激酶(CKM)多克隆抗体Polyclonal Antibody to Creatine Kinase, Muscle (CKM)

kl109Fi01肌肌酸激酶(CKM)多克隆抗体Polyclonal Antibody to Creatine Kinase, Muscle (CKM)

kl109Ga01肌肌酸激酶(CKM)多克隆抗体Polyclonal Antibody to Creatine Kinase, Muscle (CKM)

kl109Hu01肌肌酸激酶(CKM)多克隆抗体Polyclonal Antibody to Creatine Kinase, Muscle (CKM)